This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens Boots Alliance (WBA) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $11.22, indicating a -0.13% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $11.18, indicating a +0.45% shift from the previous trading day.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Retail and Wholesale Names
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
by Urmimala Biswas
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
Why Walgreens Boots Alliance (WBA) Outpaced the Stock Market Today
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $11.16, moving +0.95% from the previous trading session.
Why Is Walgreens (WBA) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Walgreens (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Walgreens Boots Alliance (WBA) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) reachead $10.98 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.
CVS Soars 53% in Q1: Time to Buy the Stock Ahead of Earnings Release?
by Urmimala Biswas
Caremark, CVS Health's PBM business, is expected to have continued to play a vital role in offsetting the rising cost of branded drugs during the first quarter.
Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EZM
Walgreens Boots Alliance (WBA): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Walgreens Boots Alliance (WBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Seeking Income? 3 High Yield Stocks Worth a Look
by Derek Lewis
Dividend-paying stocks can allow investors to build a cash pile quickly. After all, isn't payday the best?
Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down
by Zacks Equity Research
WBA delivers better-than-expected earnings and revenues in the second quarter of fiscal 2025.
Walgreens (WBA) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Walgreens (WBA) give insight into how the company performed in the quarter ended February 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Walgreens Boots Alliance (WBA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 18.87% and 1.75%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?
by Urmimala Biswas
CVS Health's strong track record of stable cash generation aids it amid the broader market sell-offs due to escalating 2025 Trump tariffs.
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EZM
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Walgreens Boots Alliance (WBA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens Boots Alliance (WBA) Stock Moves -0.73%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $11.18, indicating a -0.73% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Stock Moves -0.62%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) concluded the recent trading session at $11.21, signifying a -0.62% move from its prior day's close.
CVS Stock Soars 47% YTD: Is Digital Growth Fueling a Buy Opportunity?
by Urmimala Biswas
CVS Health is consistently increasing investments in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products.
Is Walgreens Boots Alliance (WBA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $10.75 in the latest trading session, marking a -0.78% move from the prior day.
Are Retail-Wholesale Stocks Lagging MercadoLibre (MELI) This Year?
by Zacks Equity Research
Here is how MercadoLibre (MELI) and Walgreens Boots Alliance (WBA) have performed compared to their sector so far this year.